Sarepta Therapeutics Files Q1 2025 10-Q

Ticker: SRPT · Form: 10-Q · Filed: May 6, 2025 · CIK: 873303

Sentiment: neutral

Topics: 10-Q, pharmaceutical, financials

TL;DR

Sarepta's Q1 2025 10-Q is in: financials and operations update for Elevidys.

AI Summary

Sarepta Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including information related to its product Elevidys and supply agreements. The company's financial reporting period covers the first quarter of 2025.

Why It Matters

This filing provides investors and stakeholders with an update on Sarepta's financial health and operational progress, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Sarepta faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.

What is the company's primary industry classification?

Sarepta Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

When was Sarepta Therapeutics, Inc. incorporated?

The company was incorporated in Delaware (DE).

What specific product is mentioned in relation to financial reporting?

The product 'Elevidys' is mentioned in the context of financial reporting, specifically as a member of 'srpt:ElevidysMember'.

What is the filing date of this 10-Q report?

The filing date is 20250506.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Sarepta Therapeutics, Inc. (SRPT).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing